SOLAR
EFFICACY
Every-2-month CABENUVA was noninferior to daily oral BIKTARVY1
SOLAR, a phase 3b clinical trial, is the first head-to-head switch study comparing every-2-month CABENUVA with daily oral BIKTARVY1,2
SOLAR
SAFETY
CABENUVA real-world studies reinforce SOLAR
AE=adverse event; BMI=body mass index; CI=confidence interval; CVF=confirmed virologic failure; HBV=hepatitis B virus; INSTI=integrase strand-transfer inhibitor; IQR=interquartile range; ISR=injection site reaction; ITT-E=intent-to-treat exposed; M=month; mITT-E=modified intent-to-treat exposed; NNRTI=non-nucleoside reverse transcriptase inhibitor; OLI=oral lead-in; PI=protease inhibitor; RAM=resistance-associated mutation; RPV=rilpivirine.
References:
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
- Data on file. ViiV Healthcare group of companies. Durham, NC.
- Eu B, Oka S, Sims J, et al. Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and body mass index: a subgroup analysis of the phase 3b SOLAR study. Poster presented at: IAS Conference on HIV Science; July 23-26, 2023; Virtual and Brisbane, Australia. EPB0221.
- Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76(9):1646-1654.
PMUS-CBRWCNT250025